- Page 1 and 2:
Managing Challenges Solvay Global A
- Page 3 and 4:
Key fi gures - Solvay Group Financi
- Page 5 and 6:
February 1 Caprolactones Solvay con
- Page 7 and 8:
Apart from increasing our competiti
- Page 9 and 10:
and optional overtime and taking of
- Page 11 and 12:
... and Long-Term Value Creation Th
- Page 13 and 14:
and using it without limits, the pi
- Page 15 and 16:
Chemicals Sales: EUR 3.1 billion -
- Page 17 and 18:
2008 : operating result down 19% on
- Page 19 and 20:
EUR million 2007 2008 2008/2007 GRO
- Page 21 and 22:
Balance sheet Total Equity stood at
- Page 23 and 24:
Current profi t before taxes amount
- Page 25 and 26:
Robot in Weesp. This 384 wells plat
- Page 27 and 28:
Key fi gures [EUR million] 2006 200
- Page 29 and 30:
Flagship Products in 2008 Therapeut
- Page 31 and 32:
Sales of less important products In
- Page 33 and 34:
Sodium bicarbonate. Sodium bicarbon
- Page 35 and 36:
Key fi gures [EUR million] 2006 200
- Page 37 and 38:
natural resources and limit waste d
- Page 39 and 40:
The Organic cluster: Molecular Solu
- Page 41 and 42:
Solvay specialty polymers The outst
- Page 43 and 44:
Key fi gures [EUR million] 2006 200
- Page 45 and 46:
Technological leadership through Re
- Page 47 and 48:
production capacities have been inc
- Page 49 and 50:
New Business Development OLED. Orga
- Page 51 and 52:
future) reacts with atmospheric oxy
- Page 53 and 54:
Increasing cultural diversity. Solv
- Page 55 and 56:
New career management process In 20
- Page 57 and 58:
The 5x5 Matrix The 5x5 Matrix is th
- Page 59 and 60:
Investors: responding to growing in
- Page 61 and 62:
Financial Statements The following
- Page 63 and 64:
Consolidated balance sheet EUR Mill
- Page 65 and 66:
Minority interests The increase in
- Page 67 and 68:
• IFRIC 15 Agreements for the con
- Page 69 and 70:
9. Research and Development costs R
- Page 71 and 72:
Key assumptions & key sources of es
- Page 73 and 74:
General description of the segments
- Page 75 and 76:
Information per primary segment for
- Page 77 and 78:
For the Pharmaceuticals Sector, whi
- Page 79 and 80:
- Current tax represents the tax pa
- Page 81 and 82:
Other information All the Group’s
- Page 83 and 84: The acquisitions in 2008 consist ma
- Page 85 and 86: Alexandria Sodium Carbonate On 17 O
- Page 87 and 88: (20) Capital increase / redemption
- Page 89 and 90: Consolidated balance sheet (22) Int
- Page 91 and 92: (24) Tangible assets (including fi
- Page 93 and 94: (26) Other investments EUR million
- Page 95 and 96: (29) Provisions EUR Million Employe
- Page 97 and 98: The amounts recorded in the balance
- Page 99 and 100: Actuarial assumptions used in deter
- Page 101 and 102: - the risks attached to ongoing lit
- Page 103 and 104: Fair value of fi nancial debts For
- Page 105 and 106: ) Balance sheet risk The Group’s
- Page 107 and 108: Financial instruments IAS 39 defi n
- Page 109 and 110: (32) Assets held for sale and liabi
- Page 111 and 112: Management of Risks Acting responsi
- Page 113 and 114: In reference to Raw Materials, in a
- Page 115 and 116: Since 2007 a compliance organizatio
- Page 117 and 118: Participation in venture capital fu
- Page 119 and 120: Compensation report 1. Description
- Page 121 and 122: affi liated to the Pension Regulati
- Page 123 and 124: Companies leaving the Group Country
- Page 125 and 126: SolVin France SA, Paris 75 Pl Vival
- Page 127 and 128: Solvay Soda Ash Joint Venture, Hous
- Page 129 and 130: FINLAND Pipelife Finland OY, Oulu 5
- Page 131 and 132: Summary fi nancial statements of So
- Page 133: STATUTORY AUDITOR’S REPORT To the
- Page 137 and 138: Introduction This report presents t
- Page 139 and 140: The Board of Directors noted their
- Page 141 and 142: notice of the meeting by mail at th
- Page 143 and 144: Year of birth Year of 1st appointme
- Page 145 and 146: eing a non-executive director of a
- Page 147 and 148: 4.5.2. The Audit Committee At Janua
- Page 149 and 150: corresponding to the decision or re
- Page 151 and 152: which remained valid for the 2008 f
- Page 153 and 154: Manager, a member of the Executive
- Page 155 and 156: EUR The Solvay share compared with
- Page 157 and 158: ANNEX 1 Audit Committee Mission Sta
- Page 159 and 160: during the 30 days preceding the st
- Page 161 and 162: Executive Committee 1 | Christian J
- Page 163 and 164: ABAF: Belgian Financial Analysts As
- Page 165 and 166: Shareholders’ Diary - Tuesday May